Journal
VACCINE
Volume 31, Issue 21, Pages 2500-2505Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.10.016
Keywords
Adjuvants; Innate immunity; Vaccines; Newborn; Infant; Immunization
Categories
Funding
- Burroughs Wellcome Fund
- Michael Smith Foundation
- Canadian Institutes of Health Research
- US National Institute of Allergy and Infectious Diseases
- GlaxoSmithKline
- Merck
- Advaxis
- Allergen NCE
- government of the Walloon Region
- GlaxoSmithKline Biologicals
- Fonds de la Recherche Scientifique (FRS-FNRS, Belgium)
- U.S. National Institutes of Health (NIH) [R01AI100135-01]
- Bill & Melinda Gates Foundation [OPPGH5284, OPP1035192]
- VentiRx Pharmaceuticals
- FNRS
- Bill and Melinda Gates Foundation [OPP1035192, OPPGH5284] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Subunit vaccine formulations often include adjuvants that primarily stimulate innate immune cells. While young infants represent the major target population for vaccination, effective immunization in this age group remains a challenge. Many parameters of innate immune responses differ quantitatively and qualitatively from newborns to infants and adults, revealing a highly regulated developmental program. Herein, we discuss the potential implications of innate immune ontogeny for the activity of adjuvants contained in licensed infant vaccines, as well as future directions for rational design of adjuvanted vaccines for this age group. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available